Healthcare
TG Therapeutics, Inc.(TGTX)
Live Price
Offline$53.22
+3.34% today
1Y Change
+38.24%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $5.40B
- Revenue Growth
- +87.3%
- EPS Growth
- +1837.5%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TG Therapeutics, Inc. (TGTX) is a Healthcare stock with a market cap of $5.40B and listed on NASDAQ. The stock last traded around $53.22 and up 38.2% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +87.3%, EPS growth of +1837.5%, a dividend yield of 0.0%. What stands out right now is revenue +87.3%, EPS +1837.5%, free cash flow +38.4% with operating margin 20.0% and ROIC 13.5%. Valuation already assumes a fairly strong business story at P/E 10.8 and price/sales 8.8. Stock Foundry combines TGTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+87.3% vs +7.6% peer median
Operating Margin
Near sector median
+20.0% vs +19.4% peer median
P/E
Below sector median
10.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +87.3% and EPS at +1837.5%, with operating margin around 20.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | +1.1% | +20.8% | +2.6% |
2026 Feb 26, 2026 | -60.0% | -2.6% | -6.1% | +3.5% |
2025 Nov 3, 2025 | +912.5% | +0.4% | -10.1% | -9.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TGTX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TGTX Max Drawdown
-32.66%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TGTX and SPY.
Company Overview
TG Therapeutics, Inc.
NASDAQ Capital Market
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
- Leadership
- Michael S. Weiss
- IPO Date
- May 3, 2010
- Employees
- 352
- Street Address
- 2 Gansevoort Street
- Mailing
- Morrisville, NY, 10014
- Region
- Morrisville, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 554 4484
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 10.8
- EV/EBITDA
- 41.6
- Price/Sales
- 8.8
- Price/Book
- 7.5
Growth
- Revenue
- +87.3%
- EPS
- +1837.5%
- Free Cash Flow
- +38.4%
Profitability
- Gross Margin
- 83.6%
- Operating Margin
- 20.0%
- Net Margin
- 72.6%
- ROE
- 101.1%
- ROIC
- 13.5%
Balance Sheet
- Debt/Equity
- 0.40
- Current Ratio
- 4.10
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.